Lexaria Bioscience Corp Stock Performance

LEXX Stock  USD 0.73  0.07  10.61%   
The company secures a Beta (Market Risk) of 1.84, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexaria Bioscience will likely underperform. At this point, Lexaria Bioscience Corp has a negative expected return of -0.39%. Please make sure to verify Lexaria Bioscience's potential upside and day median price , to decide if Lexaria Bioscience Corp performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Lexaria Bioscience Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor
1:30
Dividend Date
2021-01-12
Last Split Date
2021-01-12
1
Will Lexaria Bioscience Corp. stock deliver consistent dividends - Analyst Upgrade Expert Curated Trade Setups - newser.com
11/18/2025
2
Lexaria Bioscience Corp Stock Analysis and Forecast - Volatility Index Analysis Unlock Long-Term Capital Growth Ideas - earlytimes.in
11/26/2025
3
Lexaria Bioscience Upgraded at Wall Street Zen
12/02/2025
4
Lexaria Bioscience Corp. Announces Closing of 3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - TradingView Track All Markets
12/16/2025
5
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50 percent Versus Novo Nordisks Rybelsus
12/23/2025
6
Growth Value Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable - 2025 Key Lessons Technical Pattern Based Buy Signals - moha.gov.vn
01/02/2026
7
Institution Moves Is Lexaria Bioscience Corp stock a bargain at current levels - 2025 Valuation Update Real-Time Buy Signal Notifications - moha.gov.vn
01/13/2026
8
Risk Check Will Lexaria Bioscience Corp outperform small cap indexes - Weekly Stock Report Reliable Price Action Trade Plans - baoquankhu1.vn
01/20/2026
9
Jobs Data Will Lexaria Bioscience Corp Equity Warrant stock go up in YEAR - 2025 Growth vs Value AI Enhanced Trade Execution Alerts - baoquankhu1.vn
02/02/2026
10
Lexaria Announces Positive Final Results from Human Pilot Study 5
02/05/2026
Begin Period Cash Flow6.5 M
Total Cashflows From Investing Activities-243 K

Lexaria Bioscience Relative Risk vs. Return Landscape

If you would invest  112.00  in Lexaria Bioscience Corp on November 11, 2025 and sell it today you would lose (39.00) from holding Lexaria Bioscience Corp or give up 34.82% of portfolio value over 90 days. Lexaria Bioscience Corp is currently does not generate positive expected returns and assumes 7.5828% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Lexaria, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Lexaria Bioscience is expected to under-perform the market. In addition to that, the company is 9.4 times more volatile than its market benchmark. It trades about -0.05 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of volatility.

Lexaria Bioscience Target Price Odds to finish over Current Price

The tendency of Lexaria Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.73 90 days 0.73 
about 77.69
Based on a normal probability distribution, the odds of Lexaria Bioscience to move above the current price in 90 days from now is about 77.69 (This Lexaria Bioscience Corp probability density function shows the probability of Lexaria Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.84 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Lexaria Bioscience will likely underperform. Additionally Lexaria Bioscience Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Lexaria Bioscience Price Density   
       Price  

Predictive Modules for Lexaria Bioscience

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Lexaria Bioscience Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lexaria Bioscience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.040.728.24
Details
Intrinsic
Valuation
LowRealHigh
0.081.669.18
Details
2 Analysts
Consensus
LowTargetHigh
4.104.505.00
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.29-0.19-0.08
Details

Lexaria Bioscience Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Lexaria Bioscience is not an exception. The market had few large corrections towards the Lexaria Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Lexaria Bioscience Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Lexaria Bioscience within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.39
β
Beta against Dow Jones1.84
σ
Overall volatility
0.21
Ir
Information ratio -0.04

Lexaria Bioscience Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Lexaria Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Lexaria Bioscience Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Lexaria Bioscience generated a negative expected return over the last 90 days
Lexaria Bioscience has high historical volatility and very poor performance
Lexaria Bioscience has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 705.92 K. Net Loss for the year was (11.91 M) with profit before overhead, payroll, taxes, and interest of 522 K.
Lexaria Bioscience Corp currently holds about 7.34 M in cash with (10.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Lexaria Bioscience has a frail financial position based on the latest SEC disclosures
Latest headline from thenewswire.com: Lexaria Announces Positive Final Results from Human Pilot Study 5

Lexaria Bioscience Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Lexaria Stock often depends not only on the future outlook of the current and potential Lexaria Bioscience's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lexaria Bioscience's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18 M
Cash And Short Term InvestmentsM

Lexaria Bioscience Fundamentals Growth

Lexaria Stock prices reflect investors' perceptions of the future prospects and financial health of Lexaria Bioscience, and Lexaria Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lexaria Stock performance.

About Lexaria Bioscience Performance

Evaluating Lexaria Bioscience's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lexaria Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lexaria Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.52)(0.55)
Return On Capital Employed 0.14  0.14 
Return On Assets(0.52)(0.55)
Return On Equity(0.89)(0.94)

Things to note about Lexaria Bioscience Corp performance evaluation

Checking the ongoing alerts about Lexaria Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lexaria Bioscience Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Lexaria Bioscience generated a negative expected return over the last 90 days
Lexaria Bioscience has high historical volatility and very poor performance
Lexaria Bioscience has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 705.92 K. Net Loss for the year was (11.91 M) with profit before overhead, payroll, taxes, and interest of 522 K.
Lexaria Bioscience Corp currently holds about 7.34 M in cash with (10.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Lexaria Bioscience has a frail financial position based on the latest SEC disclosures
Latest headline from thenewswire.com: Lexaria Announces Positive Final Results from Human Pilot Study 5
Evaluating Lexaria Bioscience's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Lexaria Bioscience's stock performance include:
  • Analyzing Lexaria Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lexaria Bioscience's stock is overvalued or undervalued compared to its peers.
  • Examining Lexaria Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Lexaria Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lexaria Bioscience's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Lexaria Bioscience's stock. These opinions can provide insight into Lexaria Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Lexaria Bioscience's stock performance is not an exact science, and many factors can impact Lexaria Bioscience's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.